Table 1.

Participants’ demographics and clinical characteristics

Patient	Age at diagnosis (years)	Sex	Diagnosis	Metastases at diagnosis	Chemotherapy regimen	Total number of cycles with ifosfamidea	Cumulative dose of ifosfamide (g/m2)a	Time interval between last dose of ifosfamide and long-term evaluation of renal function (months)	Long-term nephrotoxicityc
1	17	M	Emb. Rhab.	No	IVA	7	62	64	Grade 1
2	13	F	Ewing sarcoma	Yes	VIDE	14	97	42	Grade 1
3	12	M	Ewing sarcoma	No	VIDE	7	60	89	No
4	12	M	Ewing sarcoma	No	VIDE	7	59	56	No
5	14	F	Emb. Rhab.	No	IVA	9	54	98	Grade 1
6	13	F	Ewing sarcoma	Yes	VIDE	11	80	Not availableb	Not evaluableb
7	12	M	Ewing sarcoma	No	VIDE	6	54	29	No
8	8	M	Ewing sarcoma	Yes	VIDE	14	102	Not availableb	Not evaluableb
9	10	M	Emb. Rhab.	No	IVA	4	24	31	Grade 1
10	10	M	Alv. Rhab.	No	IVA	9	54	13	Grade 1
11	17	M	Ewing sarcoma	No	VIDE	6	53	21	Grade 1
12	16	F	Ewing sarcoma	Yes	VIDE	14	99	30	Grade 1
13	17	M	Emb. Rhab.	No	IVA	9	50	74	Grade 2
14	11	M	Ewing sarcoma	No	VIDE	7	59	14	No
15	16	F	Ewing sarcoma	No	VIDE	7	54	21	No

Emb. Rhab., Embryonal rhabdomyosarcoma; Alv. Rhab., Alveolar rhabdomyosarcoma; IVA regimen, Ifosfamide, vincristine and actinomycin D; VIDE regimen, Etoposide, ifosfamide, adriamycine and vincristine

^aIncluding cycles and doses of ifosfamide received during IFOS01 study (corresponding to induction treatment) and after induction. ^bPatient’s death before long-term follow-up visit. ^cNephrotoxicity using the score from Skinner et al.